Trials: PNC Vaccine

Phase 3 N=938 Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

Pneumococcal Infections

Primary: Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC Relative to 23vPS (Vax 1 / Year 0) — 81; 55; 55; 49 geometric mean titer

Wyeth is now a wholly owned subsidiary of Pfizer Results May 2011 3.3% serious AE View details

Phase 3 N=331 Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

HIV Infections · Pneumococcal Infections

Primary: Geometric Mean Fold Rise (GMFR) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After Dose 2 of 13vPnC to 1 Month After Dose 3 of 13vPnC…

Pfizer Results Jun 2013 4.2% serious AE View details

Phase 3 N=619 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

Vaccines, Pneumococcal

Primary: Percentage of Participants Achieving Predefined Meningococcal C Serum Bactericidal Assay (SBA) Titer of ≥ 1:8, and a Predefined Antibody Level for Diphtheria in 13vPnC…

Wyeth is now a wholly owned subsidiary of Pfizer Results Aug 2012 3.2% serious AE View details

Phase 3 N=500 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.

Pneumococcal Vaccines

Primary: Percentage of Participants Achieving a Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal To (>=) 0.35 Microgram Per…

Pfizer Results Mar 2015 0.1% serious AE View details

Phase 3 N=1,796 Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Pneumococcal Disease

Primary: Percentage of Participants With Local Reactions Within 10 Days After Vaccination With 20vPnC — 6.3; 7.4; 4.0; 3.3 Percentage of participants

Pfizer Results Jul 2022 3.7% serious AE View details

Phase 3 N=89 Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine

Invasive Pneumococcal Disease

Primary: Percentage of Participants Achieving a Predefined Serotype-specific Immunoglobulin G (IgG) Antibody Concentration Greater Than or Equal to ( ≥) 0.35 Micrograms Per…

Wyeth is now a wholly owned subsidiary of Pfizer Results Jan 2011 0.0% serious AE View details

Phase 3 N=839 Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Pneumococcal Disease

Primary: Percentage of Participants Reporting Prompted Local Reactions Within 7 Days After Vaccination — 37.7; 39.1; 37.2; 15.1 Percentage of participants

Pfizer Results Apr 2023 0.6% serious AE View details

Phase 3 N=262 Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.

13-valent Pneumococcal Vaccine · Immunization · Safety

Primary: Serotype-specific Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentration (GMC) 1 Month After Single Dose of 13 Valent Pneumococcal Conjugate (13vPnC) Vaccine…

Pfizer Results Feb 2012 0.0% serious AE View details

Phase 3 N=1,160 Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults

Pneumococcal Infections

Primary: TIV Comparisons: Percentage of Participants Achieving at Least a 4-fold Increase in the Titer of the Standard Hemagglutination Inhibition Assay (HAI) — 80.3; 78.6; 58.0…

Pfizer Results Feb 2012 0.8% serious AE View details

Phase 3 N=604 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

Vaccines, Pneumococcal

Primary: Percentage of Participants Achieving Antibody Level ≥0.35 μg/mL in 13vPnC Group Relative to 7vPnC Group After the 3-Dose Infant Series — 98.2; 98.2; 77.5; 87.1…

Wyeth is now a wholly owned subsidiary of Pfizer Results Aug 2012 4.1% serious AE View details

Phase 4 N=1,199 13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India

Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) Within 1 Month After 13vPnC Vaccination — 0; 7; 0; 0 Percentage…

Pfizer Results Jul 2016 0.0% serious AE View details

Phase 3 N=720 Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

Pneumococcal Vaccines

Primary: Pneumococcal OPA Geometric Mean Titers (GMTs) for the 12 Common Serotypes for 13vPnC / 23vPS (Year 1) Versus 23vPS (Year 0) — 148; 148; 125; 80 geometric mean titer

Wyeth is now a wholly owned subsidiary of Pfizer Results May 2011 1.5% serious AE View details

Phase 4 N=882 Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE

Primary: Serotype-specific Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for 13 Pneumococcal Serotypes — 75; 83; 41; 49 titer

Pfizer Results Jul 2016 1.2% serious AE View details

Phase 3 N=400 A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.

Pneumococcal Disease

Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination — 1.0; 1.0; 0.0; 0.5 Percentage of participants

Pfizer Results Oct 2024 0.0% serious AE View details

Phase 3 N=962 Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated

Healthy

Primary: Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titer (GMT) Antibody Persistence 1 Year After Vaccination (Vax) 2 in Parent Study…

Pfizer Results Jun 2012 0.0% serious AE View details

Phase 4 N=200 A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India

Pneumococcal Disease

Primary: Percentage of Participants With Prompted Local Reactions Within 7 Days After Vaccination — 1.5; 6.5; 63.0 Percentage

Pfizer Results Apr 2024 0.0% serious AE View details

Phase 1 N=800 Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

Pneumococcal Infections

Primary: Concentration of Serotype-Specific IgG Antibodies — 15.26; 0.01; 3.1; 0.06 ug/ml

Wyeth is now a wholly owned subsidiary of Pfizer Results May 2009 View details

Phase 3 N=303 Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

HIV Infections · Pneumococcal Infections

Primary: Geometric Mean Fold Rise (GMFR) for Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody From 1 Month After 13vPnC Dose 2 to 1 Month After 13vPnC Dose 3 in All…

Pfizer Results Nov 2014 0.5% serious AE View details

Phase 3 N=324 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico

Pneumococcal Infections

Primary: Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination — 120; 84; 88; 89 titer

Pfizer Results Jan 2013 0.6% serious AE View details

Phase 3 N=606 Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants

Vaccines, Pneumococcal

Primary: Percentage of Participants Reporting Pre-Specified Local Reactions — 32.1; 30.0; 30.4; 36.7 Percentage of Participants

Wyeth is now a wholly owned subsidiary of Pfizer Results Feb 2013 2.5% serious AE View details

Phase 3 N=709 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India

Pneumococcal Infections

Primary: Percentage of Participants Achieving a Predefined Antibody Level of Greater Than or Equal to 0.35 Micrograms (Mcg)/mL, 1 Month After the Infant Series. — 97.0; 97.9…

Wyeth is now a wholly owned subsidiary of Pfizer Results Nov 2010 2.1% serious AE View details

Phase 3 N=1,255 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

Pneumococcal Disease

Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study Population — 20.7; 22.7; 4.5; 4.8 Percentage of participants

Pfizer Results May 2023 5.9% serious AE View details

N/A N=300 A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS

Immunogenicity, Vaccine

Primary: Geometric Mean Concentrations (GMCs) of Pneumococcal Immunoglobulin G (IgG) by Cohort — 1.55; 0.12; 0.42; 0.07 microgram per milliliter (µg/mL)

Pfizer Results Oct 2023 0.0% serious AE View details

Phase 3 N=1,116 Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

Influenza

Primary: Percentage of Participants Achieving at Least 4-fold Increase in Titer for Concomitant Trivalent Inactivated Influenza Vaccine (TIV) Antigens 1 Month After Dose 1…

Pfizer Results Apr 2015 1.1% serious AE View details

Phase 4 N=100 Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In India

Vaccines

Primary: Percentage of Participants Reporting Local Reactions by Severity Within 7 Days After Vaccination — 14.9; 14.9; 0; 0 percentage of participants

Pfizer Results Apr 2020 1.0% serious AE View details

Phase 3 N=613 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Vaccines, Pneumococcal

Primary: Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria, Tetanus, Hemophilus Influenza Type b (Hib), Poliomyelitis (Type 1, 2, 3), Pertussis Toxin…

Wyeth is now a wholly owned subsidiary of Pfizer Results Aug 2012 1.5% serious AE View details

Phase 4 N=200 Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.

13-valent Pneumococcal Vaccine · Premature Birth · Immunization

Primary: Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter…

Pfizer Results Feb 2015 7.6% serious AE View details

N/A N=297 Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers

Pneumococcal Disease

Primary: Prevalence of Streptococcus Pneumoniae in Nasopharynx — 76; 43; 86; 46 Participants

PATH Results Feb 2020 1.7% serious AE View details

Phase 3 N=806 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Infections, Streptococcal

Primary: Number of Subjects Reporting Rectal Temperature Above (>) 39.0 Degrees Celsius (°C) — 31; 6; 30; 13 Participants

GlaxoSmithKline Results Dec 2018 11.3% serious AE View details

Phase 2 N=220 Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine

Pneumococcal Vaccines

Primary: Solicited Local Adverse Events (AEs) — 0; 0; 0; 0 events

Inventprise Inc. Results Mar 2026 0.4% serious AE View details

Clinical Trial Search

Phase 3 N=938 Study Evaluating The Safety, Tolerability And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine (13vPnC)

Phase 3 N=331 Safety & Immunogenicity of 13vPnC in HIV-Infected Subjects Aged 18 or Older Who Were Previously Immunized With 23vPS

Phase 3 N=619 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

Phase 3 N=500 13vPnC Multidose Vial Safety, Tolerability and Immunogenicity Study in Healthy Infants.

Phase 3 N=1,796 Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Phase 3 N=89 Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine

Phase 3 N=839 Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age

Phase 3 N=262 Study Evaluating Antibody Response Of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) 24 Months After Toddler Dose.

Phase 3 N=1,160 Study Evaluating Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine With Influenza Vaccine in Adults

Phase 3 N=604 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants.

Phase 4 N=1,199 13-valent Pneumococcal Conjugate Vaccine Study in Adults and Children in India

Phase 3 N=720 Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

Phase 4 N=882 Concomitant Administration of 13-valent Pneumococcal Conjugate Vaccine (13vPnC) With Influenza Vaccine in 23-valent Pneumococcal Polysaccharide (23vPS) Pre-vaccinated Adults.

Phase 3 N=400 A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.

Phase 3 N=962 Study Evaluating Persistence Of Antibody Response Elicited By 13vPnC In Healthy Adults Previously Vaccinated

Phase 4 N=200 A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India

Phase 1 N=800 Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants

Phase 3 N=303 Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in HIV-Infected Subjects 6 Years of Age or Older Who Are Naive to Pneumococcal Vaccine

Phase 3 N=324 13-valent Pneumococcal Conjugate Vaccine Study in Adults => 50 Years of Age in Mexico

Phase 3 N=606 Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Infants

Phase 3 N=709 Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants in India

Phase 3 N=1,255 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants

N/A N=300 A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHINESE CHILDREN AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS

Phase 3 N=1,116 Study Evaluating 13 Valent Pneumococcal Conjugate Vaccine With Trivalent Inactivated Influenza Vaccine

Phase 4 N=100 Study To Describe The Safety Of 13-valent Pneumococcal Conjugate Vaccine In Children 6 To 17 Years Of Age In India

Phase 3 N=613 Study to Evaluate a 13-valent Pneumococcal Conjugate Vaccine in Infants

Phase 4 N=200 Study Evaluating a 13-valent Pneumococcal Conjugate Vaccine in Preterm Compared to Term Infants.

N/A N=297 Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers

Phase 3 N=806 Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine

Phase 2 N=220 Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine